drugset / Trial / NCT01125657

A Study to Compare the Pharmacokinetics of YM150 Formulation-A and Formulation-B

NCT01125657

Phase 1 Completed 44 enrolled Astellas Pharma Inc
RandomizedCrossoverOpen-label

Summary

This study is to compare its pharmacokinetics profile of two YM150 formulations by 2x2 crossover method.

Timeline

Start
2010-02
Primary completion
2010-03
Completion
2010-03

Drugs

EvaluationDrugModalityDoseRoute
Subject darexaban Small molecule Oral

Indications

No indication recorded.